186 related articles for article (PubMed ID: 33914382)
1. The utility of ThyroSeq
Li W; Justice-Clark T; Cohen MB
Cytopathology; 2021 Jul; 32(4):505-512. PubMed ID: 33914382
[TBL] [Abstract][Full Text] [Related]
2. Molecular Testing Has Limited Utility in the Surgical Evaluation of Bethesda III Thyroid Nodules.
Scola WH; Linhares SM; Handelsman RS; Picado O; Khan ZF; Farrá JC; Lew JI
J Surg Res; 2021 Dec; 268():209-213. PubMed ID: 34358733
[TBL] [Abstract][Full Text] [Related]
3. Repeat Fine-Needle Aspiration With Molecular Analysis in Management of Indeterminate Thyroid Nodules.
Papazian MR; Dublin JC; Patel KN; Oweity T; Jacobson AS; Brandler TC; Givi B
Otolaryngol Head Neck Surg; 2023 Apr; 168(4):738-744. PubMed ID: 35412868
[TBL] [Abstract][Full Text] [Related]
4. ThyroSeq
Rivas AM; Nassar A; Zhang J; Casler JD; Chindris AM; Smallridge R; Bernet V
Endocr Pract; 2018 Sep; 24(9):780-788. PubMed ID: 30084677
[TBL] [Abstract][Full Text] [Related]
5. Hurthle cell predominance impacts results of Afirma gene expression classifier and ThyroSeq molecular panel performance in indeterminate thyroid nodules.
Parajuli S; Jug R; Ahmadi S; Jiang XS
Diagn Cytopathol; 2019 Nov; 47(11):1177-1183. PubMed ID: 31348619
[TBL] [Abstract][Full Text] [Related]
6. Negative Results on Thyroid Molecular Testing Decrease Rates of Surgery for Indeterminate Thyroid Nodules.
Jug R; Parajuli S; Ahmadi S; Jiang XS
Endocr Pathol; 2019 Jun; 30(2):134-137. PubMed ID: 30825100
[TBL] [Abstract][Full Text] [Related]
7. Targeted Next Generation Sequencing with ThyroSeq v2.1 for Indeterminate Thyroid Nodules in Clinical Practice.
Witt RL
Del Med J; 2016 Dec; 88(12):366-372. PubMed ID: 29461717
[TBL] [Abstract][Full Text] [Related]
8. ThyroSeq overview on indeterminate thyroid nodules: An institutional experience.
Sirotnikov S; Griffith CC; Lubin D; Zhang C; Saba NF; Li D; Kornfield A; Chen A; Shi Q
Diagn Cytopathol; 2024 Jul; 52(7):353-361. PubMed ID: 38554032
[TBL] [Abstract][Full Text] [Related]
9. Evaluation of ThyroSeq v2 performance in thyroid nodules with indeterminate cytology.
Valderrabano P; Khazai L; Leon ME; Thompson ZJ; Ma Z; Chung CH; Hallanger-Johnson JE; Otto KJ; Rogers KD; Centeno BA; McIver B
Endocr Relat Cancer; 2017 Mar; 24(3):127-136. PubMed ID: 28104680
[TBL] [Abstract][Full Text] [Related]
10. Performance of a multigene genomic classifier and clinical parameters in predicting malignancy in a Southeast Asian cohort of patients with cytologically indeterminate thyroid nodules.
Yang SP; Nga ME; Bundele MM; Chiosea SI; Tan SH; Lum JHY; Parameswaran R; Lim MY; Li H; Cheah WK; Sek KS; Tan ATH; Loh TKS; Ngiam KY; Tan WB; Huang X; Ho TWT; Lim KH; Lim CM; Singaporewalla RM; Rao AD; Rao NCL; Chua DYK; Chin DC; Wald AI; LiVolsi VA; Nikiforov YE; Tai ES
Cancer Cytopathol; 2024 May; 132(5):309-319. PubMed ID: 38319805
[TBL] [Abstract][Full Text] [Related]
11. Bethesda III and IV Thyroid Nodules Managed Nonoperatively After Molecular Testing With Afirma GSC or Thyroseq v3.
Kim NE; Raghunathan RS; Hughes EG; Longstaff XR; Tseng CH; Li S; Cheung DS; Gofnung YA; Famini P; Wu JX; Yeh MW; Livhits MJ
J Clin Endocrinol Metab; 2023 Aug; 108(9):e698-e703. PubMed ID: 36995878
[TBL] [Abstract][Full Text] [Related]
12. Malignancy rates for Bethesda III and IV thyroid nodules: a retrospective study of the correlation between fine-needle aspiration cytology and histopathology.
Yaprak Bayrak B; Eruyar AT
BMC Endocr Disord; 2020 Apr; 20(1):48. PubMed ID: 32293401
[TBL] [Abstract][Full Text] [Related]
13. Single Institution Experience with Afirma and Thyroseq Testing in Indeterminate Thyroid Nodules.
Gortakowski M; Feghali K; Osakwe I
Thyroid; 2021 Sep; 31(9):1376-1382. PubMed ID: 33764195
[No Abstract] [Full Text] [Related]
14. ThyroSeq v3 for Bethesda III and IV: An institutional experience.
Desai D; Lepe M; Baloch ZW; Mandel SJ
Cancer Cytopathol; 2021 Feb; 129(2):164-170. PubMed ID: 33030808
[TBL] [Abstract][Full Text] [Related]
15. Performance of a Multigene Genomic Classifier in Thyroid Nodules With Indeterminate Cytology: A Prospective Blinded Multicenter Study.
Steward DL; Carty SE; Sippel RS; Yang SP; Sosa JA; Sipos JA; Figge JJ; Mandel S; Haugen BR; Burman KD; Baloch ZW; Lloyd RV; Seethala RR; Gooding WE; Chiosea SI; Gomes-Lima C; Ferris RL; Folek JM; Khawaja RA; Kundra P; Loh KS; Marshall CB; Mayson S; McCoy KL; Nga ME; Ngiam KY; Nikiforova MN; Poehls JL; Ringel MD; Yang H; Yip L; Nikiforov YE
JAMA Oncol; 2019 Feb; 5(2):204-212. PubMed ID: 30419129
[TBL] [Abstract][Full Text] [Related]
16. ACR TI-RADS and ATA US scores are helpful for the management of thyroid nodules with indeterminate cytology.
Barbosa TLM; Junior COM; Graf H; Cavalvanti T; Trippia MA; da Silveira Ugino RT; de Oliveira GL; Granella VH; de Carvalho GA
BMC Endocr Disord; 2019 Oct; 19(1):112. PubMed ID: 31664992
[TBL] [Abstract][Full Text] [Related]
17. Preoperative detection of malignancy in fine-needle aspiration cytology (FNAC) smears with indeterminate cytology (Bethesda III, IV) by a combined molecular classifier.
Titov S; Demenkov PS; Lukyanov SA; Sergiyko SV; Katanyan GA; Veryaskina YA; Ivanov MK
J Clin Pathol; 2020 Nov; 73(11):722-727. PubMed ID: 32213552
[TBL] [Abstract][Full Text] [Related]
18. Incidental
Wright K; Fisher JC; Rothberger GD; Prescott JD; Allendorf JD; Patel K; Suh I
Surgery; 2024 Jan; 175(1):228-233. PubMed ID: 38563428
[TBL] [Abstract][Full Text] [Related]
19. The role of ThyroSeq V3 testing in the management of patients with indeterminate thyroid nodules on fine needle aspiration.
Selvaggi SM
Diagn Cytopathol; 2021 Jul; 49(7):838-841. PubMed ID: 33864719
[TBL] [Abstract][Full Text] [Related]
20. Heterogeneity in Positive Predictive Value of RAS Mutations in Cytologically Indeterminate Thyroid Nodules.
Nabhan F; Porter K; Lupo MA; Randolph GW; Patel KN; Kloos RT
Thyroid; 2018 Jun; 28(6):729-738. PubMed ID: 29665745
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]